New data on ARIAD's AP24534 and ridaforolimus accepted for presentation at ASCO 2010
 

ARIAD Pharmaceuticals, Inc. today announced that new data on AP24534, its investigational pan-BCR-ABL inhibitor, and ridaforolimus, its investigational mTOR inhibitor being developed by Merck, Sharpe & Dohme Corp., have been accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

More...